These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 27916892)

  • 21. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer.
    Agrawal A; Yang J; Murphy RF; Agrawal DK
    Exp Mol Pathol; 2006 Oct; 81(2):115-22. PubMed ID: 16919268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis.
    Van Maerken T; Vandesompele J; Rihani A; De Paepe A; Speleman F
    Cell Death Differ; 2009 Dec; 16(12):1563-72. PubMed ID: 19779493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactivation of p53: from peptides to small molecules.
    Brown CJ; Cheok CF; Verma CS; Lane DP
    Trends Pharmacol Sci; 2011 Jan; 32(1):53-62. PubMed ID: 21145600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
    Terzian T; Wang Y; Van Pelt CS; Box NF; Travis EL; Lozano G
    Mol Cell Biol; 2007 Aug; 27(15):5479-85. PubMed ID: 17526734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
    Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
    Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
    Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
    Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans.
    Coffill CR; Lee AP; Siau JW; Chee SM; Joseph TL; Tan YS; Madhumalar A; Tay BH; Brenner S; Verma CS; Ghadessy FJ; Venkatesh B; Lane DP
    Genes Dev; 2016 Feb; 30(3):281-92. PubMed ID: 26798135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
    Riemenschneider MJ; Büschges R; Wolter M; Reifenberger J; Boström J; Kraus JA; Schlegel U; Reifenberger G
    Cancer Res; 1999 Dec; 59(24):6091-6. PubMed ID: 10626796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
    Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
    Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
    Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
    Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
    Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
    Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
    Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
    Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
    Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
    J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
    Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
    Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
    Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
    Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support.
    Gebauer N; Biersack H; Czerwinska AC; Schemme J; Hardel TT; Bernard V; Rades D; Lehnert H; Luley KB; Thorns C
    Leuk Lymphoma; 2016; 57(6):1482-6. PubMed ID: 26414189
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.